Pricing Log in Create free account
Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue
+32.0%
EPS
−296.6%
Free cash flow
−52.3%
Total debt
+599.5%

Quarter to September 2026, against a year earlier

55.89 0.23 −0.41%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
32.7×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BioMarin Pharmaceutical Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 5, 2026: 23 added · 11 removed · 32 modified; 4 with only figures updated

  1. Modified · Overview

    We are a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our Founded in 1997, our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with a portfolio ofnine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.